Search

Wounds are a serious public health problem and tissue healing is a complex process that requires clinical intervention. Thus, the use of biomolecules, mainly extracted from plants, presents itself as an alternative that facilitates the innate mechanisms of tissue repair. Among the different species, it is possible to highlight the Pilocarpus microphyllus, commonly known as jaborandi, which has the imidazolic alkaloid epiisopiloturin (EPI) which has emerged in research due to its anthelmintic, anti-inflammatory and antinociceptive action. Therefore, this article aims to carry out a scientific and technological prospection of P. microphyllus and EPI focused on the treatment of wounds on publication sites and articles and national and international patents deposits. For this, a survey was carried out in the following databases: Scientific Electronic Library Online (SciELO), PubMed and Web of ScienceTM for articles and the National Institute of Industrial Property of Brazil (INPI), Latin American Patent Bank (LATIPAT), European Patent Office (EPO), World Intellectual Property Organization (WIPO) and United States Patent and Trademark Office (USPTO) for patents. The search was carried out from October to November 2021, the following descriptors were used: “Pilocarpus microphyllus”, “epiisopilloturin”, “anti-inflammatory”, “in silico” and “wounds” according to the Descriptors in Sciences of Health (DeCs), as well as combinations were performed using the Boolean operator “and”. From the articles it was possible to observe that there is no published study with the use of P. microphyllus or EPI for the treatment of wounds, however they reinforce its anti-inflammatory, antinociceptive and anthelmintic activity. In addition, conducting research in silico has emerged in recent years, expanding the field of research. In patent searches for “Pilocarpus microphyllus”, the classification that registered the highest number of deposits in technological prospecting was CIP A61K, with 68.6% frequency, followed by A01N (6.9%), C07D (5.8%) , A01H (3.4%), C12N (3.4%), A61P (2.3%), A23G (2.3%), C12P (2.3%), C07K (1.1%), A23L (1.1%), A61L (1.1%), A01P (1.1%), respectively. It is noteworthy that the largest number of patents are filed in section A (human needs) and section C (chemistry and metallurgy) of the CIP, totaling 75 and 11 records, respectively. Therefore, the use of P. mycrophyllus and EPI in the development of drugs to be used in the treatment of wounds is a promising scenario for further studies due to their biological activities, which are already well described in the scientific literature.